• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

PET radiotracer enters Alzheimer trial

Article

Bayer Schering Pharma of Germany will provide its experimental PET radiotracer florbetaben to the Swiss-based biopharmaceutical company AC Immune to evaluate the effects of a vaccine being tested to treat patients with Alzheimer´s disease.

PET radiotracer enters Alzheimer trial
Bayer Schering Pharma of Germany will provide its experimental PET radiotracer florbetaben to the Swiss-based biopharmaceutical company AC Immune to evaluate the effects of a vaccine being tested to treat patients with Alzheimer´s disease. Phase II tests have demonstrated that florbetaben can image beta-amyloid deposition in the brain. In the phase I clinical trial of ACI-24, florbetaben may indicate the vaccine dose needed to produce a therapeutic effect.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.